Navigation Links
Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
Date:7/21/2008

NEW YORK, July 21 /PRNewswire/ -- Ari Kiev, M.D., president of SPRI Clinical Trials, will be a featured speaker at the upcoming conference Wall Street Unplugged: The Trout Group Investor Seminar -- Management's Guide to Wall Street. The conference will be held on Wednesday, July 30, at Midtown Loft & Terrace, 267 Fifth Avenue in New York. The event is targeted to CEOs and CFOs at private and small and mid-cap life science companies to gain better insight into Wall Street and maximize communication with the investment community.

Dr. Kiev, a peak performance strategist and author of six books on trading psychology, will speak on "Risk-Reward and Valuation of Clinical Stage Compounds: Challenge Your Perspective." His presentation will cover investors' perceptions of early stage companies, advising biotech CEOs on the most effective ways to position clinical trial data to help achieve an optimum valuation.

"Biotech CEOs should challenge their perspectives on the industry and try to see valuation from an investor's point of view rather than that of a scientist," Dr. Kiev said. "There tends to be too much emphasis on hyperbole as to the novelty of the mechanism and the size of the market. Focusing too much on why the stock is going up or down can turn off investors who are looking for greater involvement by the company in the path to success in clinical trials."

Dr. Kiev founded SPRI (http://www.spriclinicaltrials.com) in 1970 to provide top rate clinical trial services to the pharmaceutical and biotech industry. With nearly 40 years of experience managing studies in the New York area, SPRI expanded internationally in 2003. Today, the company conducts studies throughout Eastern and Western Europe.


'/>"/>
SOURCE SPRI Clinical Trials
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
2. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
4. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
8. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
9. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... on tissue protection, repair and regeneration, today announced ... received a positive response from the U.S. FDA ... RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 is ... beta 4 ("Tß4") as the active pharmaceutical ingredient. ...
(Date:2/27/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) ... Ph.D., as President and Chief Executive Officer (CEO) and member ... Craig succeeds Richard Love , interim President and CEO ... Directors.  Dr. Craig has over 20 years of experience in ... Europe . "On behalf of ...
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud ... The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
Breaking Medicine News(10 mins):